Aktis Oncology, Inc. (AKTS) vs CeriBell, Inc. (CBLL)
A side-by-side comparison of Aktis Oncology, Inc. and CeriBell, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AKTS
Aktis Oncology, Inc.
$17.83HealthcareDelayed quote: Oct 6, 2026, 3:35 PM EDT
CBLL
CeriBell, Inc.
$24.22HealthcareDelayed quote: Oct 6, 2026, 3:35 PM EDT
Total return — AKTS vs CBLL
growth of $100 · dividends reinvested · last 1yAKTS -17.3% (-17.3%/yr)CBLL +6.6% (+6.6%/yr)CBLL compounded faster over this window
AKTS CBLL
AKTS vs CBLL: by the numbers
- •AKTS is the larger company ($952M vs $919M market cap).
- •Both run net losses; CBLL's is the smaller (-64.73% vs -727.04% net margin).
Metrics side by side
Valuation
| Metric | AKTS | CBLL |
|---|---|---|
| P/S ratio | 94.65 | 9.01 |
| P/B ratio | 1.96 | 7.16 |
Profitability
| Metric | AKTS | CBLL |
|---|---|---|
| Gross margin | 100.00% | 88.90% |
| Operating margin | -1149.52% | -68.62% |
| Net margin | -727.04% | -64.73% |
| ROE | -15.09% | -51.43% |
| ROIC | -16.54% | -46.54% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.